company background image
ABEO

Abeona Therapeutics NasdaqCM:ABEO Stock Report

Last Price

US$2.65

Market Cap

US$45.5m

7D

3.5%

1Y

-54.7%

Updated

29 Jan, 2023

Data

Company Financials +

Abeona Therapeutics Inc.

NasdaqCM:ABEO Stock Report

Mkt Cap: US$45.5m

ABEO Stock Overview

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases.

ABEO fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Abeona Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Abeona Therapeutics
Historical stock prices
Current Share PriceUS$2.65
52 Week HighUS$9.36
52 Week LowUS$2.34
Beta1.25
1 Month Change-13.96%
3 Month Change-42.27%
1 Year Change-54.72%
3 Year Change-95.12%
5 Year Change-99.30%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Mar 02
Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Aug 17
Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

Apr 28
Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

Feb 21
Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 19
How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?

What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?

Dec 15
What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?

Shareholder Returns

ABEOUS BiotechsUS Market
7D3.5%0.8%2.8%
1Y-54.7%7.1%-9.2%

Return vs Industry: ABEO underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: ABEO underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is ABEO's price volatile compared to industry and market?
ABEO volatility
ABEO Average Weekly Movement10.9%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: ABEO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: ABEO's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
197490Vish Seshadrihttps://www.abeonatherapeutics.com

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders.

Abeona Therapeutics Inc. Fundamentals Summary

How do Abeona Therapeutics's earnings and revenue compare to its market cap?
ABEO fundamental statistics
Market CapUS$45.52m
Earnings (TTM)-US$89.03m
Revenue (TTM)US$4.35m

10.5x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ABEO income statement (TTM)
RevenueUS$4.35m
Cost of RevenueUS$1.44m
Gross ProfitUS$2.90m
Other ExpensesUS$91.94m
Earnings-US$89.03m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-5.18
Gross Margin66.80%
Net Profit Margin-2,048.67%
Debt/Equity Ratio0%

How did ABEO perform over the long term?

See historical performance and comparison